IP Library Granted Patent US 10,782,307
Granted Patent B1
US 10,782,307 · App. 14/639,388 · Granted Sep 22, 2020

Use of remnant lipoprotein in the treatment and prevention of cardiovascular disease

Inventor: Krishnaji R. Kulkarni (Vestavia, AL)
Assignee: The UAB Research Foundation
G01N33/92A61P3/06A61P9/10G01N33/50C07K14/775G01N2405/00G01N2800/044G01N2800/32G01N2800/323G01N2800/324G01N2800/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,782,307
App. No.
14/639,388
Granted
Sep 22, 2020
Kind
B1
Abstract

The present disclosure provides a variety of methods based on the determination of cholesterol concentration in remnant lipoprotein and/or the determination of a remnant lipoprotein level in a sample from a subject. Such methods include, but are not limited to, a method of predicting the risk of cardiovascular disease, a method for evaluating a subject for treatment for a cardiovascular disease and a method for determining if a subject is suffering from cardiovascular disease.

Claims (16)

1. A method for evaluating a subject for treatment for a cardiovascular disease, the method comprising receiving a sample from the subject; subjecting the sample to ultracentrifugation to separate remnant lipoprotein containing IDL lipoprotein and VLDL3 lipoprotein from all other lipoproteins in the sample; determining a cholesterol concentration in the remnant lipoprotein containing IDL lipoprotein and VLDL3 lipoprotein separated from the sample; and initiating treatment for a cardiovascular disease if the cholesterol concentration in the remnant lipoprotein containing IDL lipoprotein and VLDL3 lipoprotein is greater than 30 mg/dl.

2. The method of claim 1 , wherein the IDL lipoprotein concentration in the remnant lipoprotein containing IDL lipoprotein and VLDL3 lipoprotein is greater than 20 mg/dl.

3. The method of claim 1 , wherein the VLDL3 lipoprotein concentration in the remnant lipoprotein containing IDL lipoprotein and VLDL3 lipoprotein is greater than 10 mg/dl.

4. The method of claim 1 , wherein the remnant lipoprotein consists essentially of IDL lipoprotein and VLDL3 lipoprotein.

5. The method of claim 1 , wherein the subject is a human.

6. The method of claim 1 , wherein the ultracentrifugation is density gradient ultracentrifugation and the density gradient is formed using a bottom layer having a density from 1.15 to 1.25 g/ml and a top layer having a density of 1.0 to 1.10 g/ml.

7. The method of claim 1 , wherein the cardiovascular disease is myocardial infarction, coronary heart disease, coronary artery disease, coronary death, coronary insufficiency, angina pectoris or atherosclerosis.

8. The method of claim 1 , wherein the subject is an African-American.

9. A method for evaluating a subject for treatment for a cardiovascular disease, the method comprising receiving a sample from the subject; subjecting the sample to ultracentrifugation to separate remnant lipoprotein containing IDL lipoprotein and VLDL3 lipoprotein from all other lipoproteins in the sample; determining a cholesterol concentration in the remnant lipoprotein containing IDL lipoprotein and VLDL3 lipoprotein separated from the sample; and increasing monitoring of the health of the subject, initiating preventive measures in the subject, initiating lifestyle changes in the subject to reduce the risk of cardiovascular disease or a combination of the foregoing if the cholesterol concentration in the remnant lipoprotein containing IDL lipoprotein and VLDL3 lipoprotein is greater than 30 mg/dl.

10. The method of claim 9 , wherein the IDL lipoprotein concentration in the remnant lipoprotein containing IDL lipoprotein and VLDL3 lipoprotein is greater than 20 mg/dl.

11. The method of claim 9 , wherein the VLDL3 lipoprotein concentration in the remnant lipoprotein containing IDL lipoprotein and VLDL3 lipoprotein is greater than 10 mg/dl.

12. The method of claim 9 , wherein the remnant lipoprotein consists essentially of IDL lipoprotein and VLDL3 lipoprotein.

13. The method of claim 9 , wherein the subject is a human.

14. The method of claim 9 , wherein the ultracentrifugation is density gradient ultracentrifugation and the density gradient is formed using a bottom layer having a density from 1.15 to 1.25 g/ml and a top layer having a density of 1.0 to 1.10 g/ml.

15. The method of claim 9 , wherein the cardiovascular disease is myocardial infarction, coronary heart disease, coronary artery disease, coronary death, coronary insufficiency, angina pectoris or atherosclerosis.

16. The method of claim 9 , wherein the subject is an African-American.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2020
From: VAP DIAGNOSTICS LABORATORY INC.
To: HONG KONG MEDICAL SYSTE, CO., LTD.
Reel/Frame 051914/0659 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2016
From: THOMAS E. REYNOLDS, AS CHAPTER 7 TRUSTEE FOR THE BANKRUPTCY ESTATE OF ATHEROTECH, INC.
To: THE UAB RESEARCH FOUNDATION
Reel/Frame 040016/0989 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2016
From: KULKARNI, KRISHNAJI
To: ATHEROTECH, INC.
Reel/Frame 040000/0423 →